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Thiazolidinediones (TZDs) are anti-diabetic agents that lower plasma glucose levels by 
increasing insulin sensitivity in peripheral tissues. As a selective ligand of peroxisome 
proliferator-activated receptor (PPAR)-γ, TZDs also exert beneficial effects on lipid 
metabolism and inflammatory processes.1) Current studies have shown that TZDs 
are effective in reducing inflammatory markers2) and attenuates the progression of 
atherosclerosis.3) Also, they can exert direct influence on endothelial cell, vascular smooth 
muscle cell, and macrophage.4) Statins, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase inhibitors, are one of the most widely used medications in clinical practice. In 
addition to the benefit of statin in lowering the low-density lipoprotein (LDL) cholesterol, 
they act as anti-inflammatory agents through pleiotropic effects5) and randomized clinical 
trials have demonstrated their benefits in the primary and secondary prevention of coronary 
heart disease.6)7)
In the current issue of the Korean Circulation Journal,8) the authors evaluated the effect of 
the addition of pioglitazone (30 mg/day) on atherosclerotic inflammation in patients 
taking atorvastatin (20 mg/day). This study enrolled 33 statin-naïve patients with stable 
coronary artery disease (CAD) and carotid plaque ≥3 mm and subjects were randomized 
into atorvastatin (n=16) and atorvastatin plus pioglitazone (n=17) for 3 months. Serial 
18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) 
was used to evaluate the arterial inflammation before and after treatment by measuring the 
arterial target-to-background ratio (TBR) of the index vessel. After 3 months of treatment, 
a significant reduction in the TBR was observed in both groups, but the difference between 
the 2 groups showed marginal statistical significance (−0.06 in atorvastatin group and −0.10 
in atorvastatin plus pioglitazone group; p=0.058). So, the authors classified the patients 
according to the baseline TBR value, and found that addition of pioglitazone was more 
effective in patients whose baseline TBR value was above the median (−0.03 in atorvastatin 
group and −0.14 in atorvastatin plus pioglitazone group; p<0.001).
There are several studies investigating the effect of combining statin with TZD. Hanefeld et 
al.2) investigated the anti-inflammatory effect of simvastatin or pioglitazone monotherapy 
or simvastatin plus pioglitazone group in non-diabetic subjects with cardiovascular disease 
(CVD). After 3 months of treatment, simvastatin plus pioglitazone group had an additive 
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effect in reducing C-reactive protein (CRP) and matrix metalloproteinase-9 (MMP-9). 
Plasminogen activator inhibitor (PAI)-1 or homeostasis model assessment (HOMA) were 
improved in pioglitazone group only.2) Lazich et al.9) also demonstrated that simvastatin/
rosiglitazone combination had a greater reduction in CRP and increase in adiponectin 
compared to simvastatin monotherapy group in patients with metabolic syndrome.
The overall results of current study are in line with previous studies. However, unlike 
previous studies using the serum markers as an indicator of vascular inflammation, this 
study used FDG-PET/CT. FDG accumulation in atherosclerotic plaque is significantly higher 
in plaque at risk of rupture, and is known to predict restenosis after revascularization or 
mortality.10) So, FDG-PET/CT is useful in recognizing potential vulnerable plaque and 
may have a more clinical significance. Another difference is the characteristics of study 
participants. Previous studies enrolled subjects with CVD or metabolic syndrome, but they 
did not have diabetes. The current study included 22 (67%) diabetes or impaired fasting 
glucose, and extended the additive anti-inflammatory effect of pioglitazone to subjects with 
abnormal glucose tolerance.
In conclusion, despite the limitation that the overall absolute reduction in TBR after the 
addition of pioglitazone was too small as it is 0.04 or about 0.04 which is too small, this 
study demonstrated a potential role of the addition of pioglitazone in patients with sustained 
vessel inflammation after statin therapy. Further studies in larger scale subjects with various 
characteristics are warranted.
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